Moderna or Pfizer? Which Company Stands to Gain the Most From Vaccine Rollout

Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) made history when they brought their coronavirus vaccines from development to market in less than a year. So far, though, Moderna has been the only one to benefit from a share-price perspective. The company's shares soared more than 600% this year. Pfizer's stock is little changed.